Ascendis (ASND): Commercial Momentum from Weekly TransCon PTH and Recent Approvals - Initiate Buy
Ascendis has moved from pure R&D to a commercial-stage endocrinology franchise. Positive five-year TransCon PTH data, a new pediatric approval, a Nasdaq ordinary-share listing and share buybacks have set the stage for revenue growth. Technical momentum is strong, and the balance of fundamental catalysts versus execution risk supports an initiating …